ImmunoBrain is a clinical stage biopharmaceutical company transforming the fight against neurodegeneration and aging by targeting the immune system, restoring brain immune communications and boosting natural repair mechanisms. ImmunoBrain’s lead program is a proprietary antibody targeting the inhibitory immune checkpoint pathway PD-1/PD-L1, to treat Alzheimer's disease.
ImmunoBrain's novel approach for the treatment of neurodegeneration is based on years of innovative, cutting-edge scientific discoveries made in the lab of Prof. Michal Schwartz at the Weizmann Institute of Science.
Company Details
- Employees
- 19
- Founded
- -
- Address
- New York, Ny, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.immunobrain.com/
- Keywords
- Manager jobs.
- HQ
- New York, NY
Immunobrain Questions
Immunobrain's website is https://www.immunobrain.com/
Immunobrain's LinkedIn profile is https://www.linkedin.com/company/immunobrain
Immunobrain has
19 employees.
View email and phone details for 19
employees at Immunobrain.
Immunobrain's industry is
Biotechnology Research
Immunobrain's top competitors are
Neurogenesis Bio Inc.,
Neurosense Therapeutics,
Aidoc,
Nanocarry Therapeutics,
Converge Bio,
Nextpoint Therapeutics, Inc.,
Cytoreason,
Nura Bio,
Aleta Biotherapeutics,
Pluri.
Immunobrain's categories are Biotechnology Research
Immunobrain's founding year is 2015
